ResMed wins patent fight
By HME News Staff
Updated 8:30 AM CST, Tue December 12, 2023
SAN DIEGO – The U.S. Patent Trial and Appeals Board (PTAB) has invalidated the claims that New York University asserted against ResMed in a complaint for patent infringement filed in U.S. District Court, District of Delaware, in June 2021. NYU’s complaint alleged that the AutoSet and AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators infringed one or more claims of seven NYU patents. “At ResMed, we’re committed to providing patients with our leading therapy solutions,” said ResMed CEO Mick Farrell. “Our sustained investment in research and development for over 30 years has culminated in more than 9,500 issued or pending patents and designs. We applaud the PTAB’s ruling and will defend our innovations, ensuring patients continue to receive our therapy solutions, empowering them to live healthier, higher-quality lives.” ResMed filed petitions with the PTAB asserting that all the claims asserted against the company were invalid. In rulings issued from Dec. 4-7, 2023, the PTAB judges, agreeing with ResMed’s arguments, found that all the challenged claims across the seven patents were invalid. “We will continue to vigorously defend our innovations,” said Michael Rider, ResMed’s global general counsel and secretary. “The fact that our intellectual property contributed to this victory is a testament to our investment in research and development, the hard work of our inventors, and the patent protection we pursue to protect our innovation.”
Comments